| Bioactivity | BT8009 is a Nectin-4 targeting toxin conjugate with a Kd value of 2.5 nmol/L for human Nectin-4 (hNectin-4) extra-cellular domain (ECD). BT8009 consists of a Nectin-4-binding bicyclic peptide, a cleavable linker system and monomethylauristatin E (MMAE). BT8009 can be used for the research of advanced and metastatic urothelial cancer[1]. |
| Invitro | BT8009 与 MDA-MB-468 细胞膜上表达的内源性 Nectin-4 具有 “表观亲和性” 结合浓度为 12.9 nmol/L[1]。 |
| In Vivo | BT8009 (1，2 和 3 mg/kg；静脉注射，每周 1 次，5 次) 在三阴性乳腺癌和非小细胞肺癌小鼠异种移植物模型中显示出抗肿瘤作用[1]。BT8009 对大鼠的最大耐受剂量 (MTD) 为 5 mg/kg，非人灵长类动物为 1.5 mg/kg 在 5 周剂量的条件下[1]。 Animal Model: |
| Name | BT8009 |
| CAS | 2748001-89-8 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rigby M, et al. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Mol Cancer Ther. 2022 Dec 2;21(12):1747-1756. |